Hypersensitivity is an indication for drug development with over 210 pipeline drugs currently active. According to GlobalData, preregistered drugs for Hypersensitivity have a 83.33% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Hypersensitivity compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hypersensitivity overview
Hypersensitivity reactions (HR) are exaggerated immune responses categorized by Coombs and Gell. Immediate hypersensitivity reactions (IHR) include Type I, II, and III hypersensitivity reactions, mediated by antibodies such as IgE, IgM, and IgG. Type I involves IgE-mediated anaphylactic responses, seen in conditions like bronchial asthma, allergic rhinitis, and anaphylaxis. Type II involves cytotoxic-mediated responses mediated by IgG and IgM, leading to diseases like immune thrombocytopenia and autoimmune hemolytic anemia. Type III includes immunocomplex reactions, as seen in serum sickness and Arthus reaction, mediated by IgM and IgG antibodies. These reactions activate the complement system, causing inflammation and tissue damage.
For a complete picture of PTSR and LoA scores for drugs in Hypersensitivity, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
